Left ventricular outflow obstruction with TMVR is a universal risk
Transcatheter mitral valve replacement (TMVR), a non-invasive replacement of the mitral valve, is required for some patients with FMR. However, TMVR can cause a potentially fatal complication known as left ventricular outflow tract obstruction (LVOTO), and this complication is possible with all existing TMVR solutions. This means that many patients in need of TMVR are not candidates for treatment, because of the risk of LVOTO.
Existing TMVR devices need a solution for LVOTO.
In parallel to Calla, Vesalius is developing the Orion TMVR Platform, a revolutionary device and accessory to enable optimization of transcatheter mitral valve replacement, by eliminating a risk common to all existing strategies. Orion definitively prevents LVOTO when used with any suitable TMVR device, thus increasing the treatable population of patients in need of TMVR.